GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102744/primaryOK2000000GenomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102744GEOGSE0falseGene expression profiles of ibrutinib-responsive and ibrutinib non-responsive cells in ERBB4 expressing cancer cell linesBy using a unique functional protein microarray platform, we found that the FDA approved drug ibrutinib can inhibits ERBB4 activity in the same nM range as its canonical target, BTK. Cell-based assays revealed that ibrutinib treatment inhibited cell growth in some ERBB4 expressing cancer cells whereas no response was observed in other cells. Therefore, to identify global gene expression differences between ibrutinib responsive and non-responsive cancer cells, we performed RNA-Seq, and identified a signature featuring the WNT pathway that predicts growth responsiveness to ibrutinib in ERBB4 expressing cancers.2018/02/07GSE102744GSM2745964GSM2745957GSM2745958GSM2745959GSM2745960GSM2745961GSM2745962GSM274596311154SRP115576102744Homo sapiens[29398709]